Neumora Therapeutics, Inc. License Agreements

9 Contracts & Agreements
Recent Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
Exclusive License Agreement for GCase, dated September 10, 2021, by and between the Registrant and Amgen Inc
License Agreements
Neumora Therapeutics, Inc.
2023
Second Amendment to License Agreement, dated May 17, 2024, by and between the Registrant and Vanderbilt University
License Agreements
Neumora Therapeutics, Inc.
2024
First Amendment to Exclusive License Agreement for GCase, dated June 14, 2022, by and between the Registrant and Amgen, Inc
License Agreements
Neumora Therapeutics, Inc.
2023
First Amendment to License Agreement, dated July 17, 2023, by and between the Registrant and Vanderbilt University
License Agreements
Neumora Therapeutics, Inc.
2023
License Agreement, dated February 10, 2022, by and between the Registrant and Vanderbilt University
License Agreements
Neumora Therapeutics, Inc.
2023
Second Amendment to License Agreement, dated April 9, 2019, by and between BlackThorn Therapeutics, Inc. and Scripps Research Institute
License Agreements
Neumora Therapeutics, Inc.
2023
First Amendment to License Agreement, dated November 13, 2017, by and between BlackThorn Therapeutics, Inc. and Scripps Research Institute
License Agreements
Neumora Therapeutics, Inc.
2023
License Agreement, dated November 23, 2015, by and between BlackThorn Therapeutics, Inc. and Scripps Research Institute
License Agreements
Neumora Therapeutics, Inc.
2023
Exclusive License Agreement for CK1d, dated September 10, 2021, by and between the Registrant and Amgen Inc
License Agreements
Neumora Therapeutics, Inc.
2023